Comparative Pharmacology
Head-to-head clinical analysis: FEXOFENADINE HYDROCHLORIDE ALLERGY versus TAVIST 1.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FEXOFENADINE HYDROCHLORIDE ALLERGY versus TAVIST 1.
FEXOFENADINE HYDROCHLORIDE ALLERGY vs TAVIST-1
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fexofenadine is a selective peripheral H1-receptor antagonist that inhibits histamine release from mast cells and basophils.
TAVIST-1 (clemastine fumarate) is a first-generation antihistamine that acts as a competitive antagonist at histamine H1 receptors, thereby preventing histamine-mediated effects such as vasodilation, increased capillary permeability, and bronchoconstriction. It also exhibits anticholinergic and sedative properties.
60 mg orally twice daily or 180 mg orally once daily.
1.34 mg orally twice daily; maximum 8.04 mg/day.
None Documented
None Documented
Terminal elimination half-life is 14.4 hours in healthy adults. In renal impairment, half-life may be prolonged up to 59 hours.
Terminal half-life 12–15 hours; clinical dosing interval every 12 hours.
Primarily excreted unchanged in feces (80%) and urine (11%). Biliary excretion contributes to fecal elimination.
Primarily renal: ~60% unchanged; biliary/fecal: ~30% as metabolites; minor via feces.
Category A/B
Category C
Antihistamine
Antihistamine